These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28232187)

  • 1. The Caveolin-3 P104L mutation of LGMD-1C leads to disordered glucose metabolism in muscle cells.
    Deng YF; Huang YY; Lu WS; Huang YH; Xian J; Wei HQ; Huang Q
    Biochem Biophys Res Commun; 2017 Apr; 486(2):218-223. PubMed ID: 28232187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The caveolin-3 P104L mutation in LGMD-1C patients inhibits non-insulin-stimulated glucose metabolism and growth but promotes myocyte proliferation.
    Shang L; Chen T; Xian J; Deng Y; Huang Y; Zhao Q; Liang G; Liang Z; Lian F; Wei H; Huang Q
    Cell Biol Int; 2019 Jun; 43(6):669-677. PubMed ID: 30958599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caveolin-3 deficiency associated with the dystrophy P104L mutation impairs skeletal muscle mitochondrial form and function.
    Shah DS; Nisr RB; Stretton C; Krasteva-Christ G; Hundal HS
    J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):838-858. PubMed ID: 32090499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the muscular dystrophy-associated caveolin-3(P104L) mutant in adult mouse skeletal muscle specifically alters the Ca(2+) channel function of the dihydropyridine receptor.
    Weiss N; Couchoux H; Legrand C; Berthier C; Allard B; Jacquemond V
    Pflugers Arch; 2008 Nov; 457(2):361-75. PubMed ID: 18509671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caveolin-3 loss linked with the P104L LGMD-1C mutation modulates skeletal muscle mTORC1 signalling and cholesterol homeostasis.
    Shah DS; Nisr RB; Krasteva-Christ G; Hundal HS
    J Cachexia Sarcopenia Muscle; 2023 Oct; 14(5):2310-2326. PubMed ID: 37671684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point mutated caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature.
    Stoppani E; Rossi S; Meacci E; Penna F; Costelli P; Bellucci A; Faggi F; Maiolo D; Monti E; Fanzani A
    Biochim Biophys Acta; 2011 Apr; 1812(4):468-79. PubMed ID: 21182936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy.
    Ohsawa Y; Okada T; Nishimatsu S; Ishizaki M; Suga T; Fujino M; Murakami T; Uchino M; Tsuchida K; Noji S; Hinohara A; Shimizu T; Shimizu K; Sunada Y
    Lab Invest; 2012 Aug; 92(8):1100-14. PubMed ID: 22584670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of caveolin-3 induced by the dystrophy-associated P104L mutation impairs L-type calcium channel function in mouse skeletal muscle cells.
    Couchoux H; Allard B; Legrand C; Jacquemond V; Berthier C
    J Physiol; 2007 May; 580(Pt.3):745-54. PubMed ID: 17317753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic behavior of C2C12 myoblasts upon expression of the dystrophy-related caveolin-3 P104L and TFT mutants.
    Fanzani A; Stoppani E; Gualandi L; Giuliani R; Galbiati F; Rossi S; Fra A; Preti A; Marchesini S
    FEBS Lett; 2007 Oct; 581(26):5099-104. PubMed ID: 17935719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoplasmic reticulum stress response in P104L mutant caveolin-3 transgenic mice.
    Kuga A; Ohsawa Y; Okada T; Kanda F; Kanagawa M; Toda T; Sunada Y
    Hum Mol Genet; 2011 Aug; 20(15):2975-83. PubMed ID: 21610159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caveolin-3 promotes glycometabolism, growth and proliferation in muscle cells.
    Shang L; Chen T; Deng Y; Huang Y; Huang Y; Xian J; Lu W; Yang L; Huang Q
    PLoS One; 2017; 12(12):e0189004. PubMed ID: 29206848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caveolin-3 is a direct molecular partner of the Cav1.1 subunit of the skeletal muscle L-type calcium channel.
    Couchoux H; Bichraoui H; Chouabe C; Altafaj X; Bonvallet R; Allard B; Ronjat M; Berthier C
    Int J Biochem Cell Biol; 2011 May; 43(5):713-20. PubMed ID: 21262376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of insulin response in skeletal muscle cell by caveolin status.
    Oh YS; Cho KA; Ryu SJ; Khil LY; Jun HS; Yoon JW; Park SC
    J Cell Biochem; 2006 Oct; 99(3):747-58. PubMed ID: 16676355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel splice site mutation in the caveolin-3 gene leading to autosomal recessive limb girdle muscular dystrophy.
    Müller JS; Piko H; Schoser BG; Schlotter-Weigel B; Reilich P; Gürster S; Born C; Karcagi V; Pongratz D; Lochmüller H; Walter MC
    Neuromuscul Disord; 2006 Jul; 16(7):432-6. PubMed ID: 16730439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex.
    Galbiati F; Volonte D; Minetti C; Chu JB; Lisanti MP
    J Biol Chem; 1999 Sep; 274(36):25632-41. PubMed ID: 10464299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two novel CAV3 gene mutations in Japanese families.
    Sugie K; Murayama K; Noguchi S; Murakami N; Mochizuki M; Hayashi YK; Nonaka I; Nishino I
    Neuromuscul Disord; 2004 Dec; 14(12):810-4. PubMed ID: 15564037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3.
    Galbiati F; Volonte D; Minetti C; Bregman DB; Lisanti MP
    J Biol Chem; 2000 Dec; 275(48):37702-11. PubMed ID: 10973975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and pathological changes result from mutated Caveolin-3 in muscle.
    González Coraspe JA; Weis J; Anderson ME; Münchberg U; Lorenz K; Buchkremer S; Carr S; Zahedi RP; Brauers E; Michels H; Sunada Y; Lochmüller H; Campbell KP; Freier E; Hathazi D; Roos A
    Skelet Muscle; 2018 Aug; 8(1):28. PubMed ID: 30153853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caveolin-3 T78M and T78K missense mutations lead to different phenotypes in vivo and in vitro.
    Traverso M; Gazzerro E; Assereto S; Sotgia F; Biancheri R; Stringara S; Giberti L; Pedemonte M; Wang X; Scapolan S; Pasquini E; Donati MA; Zara F; Lisanti MP; Bruno C; Minetti C
    Lab Invest; 2008 Mar; 88(3):275-83. PubMed ID: 18253147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.
    Ohsawa Y; Hagiwara H; Nakatani M; Yasue A; Moriyama K; Murakami T; Tsuchida K; Noji S; Sunada Y
    J Clin Invest; 2006 Nov; 116(11):2924-34. PubMed ID: 17039257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.